Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology
PumaBiotech (@pumabiotech) / Twitter
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Is Puma Biotechnology a Buy? | The Motley Fool
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Is Puma Biotechnology (PBYI) Stock a Solid Choice Right Now?
Puma Biotechnology
Puma Biotechnology Surging
Puma Biotechnology
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology falls more than 20%
Puma Bio FDA Advisory Panel Live Blog - TheStreet
Puma Biotechnology
Puma Biotechnology Profile | FDA Health News
Puma Biotechnology, Inc. 2020 Q1 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology - Crunchbase Company Profile & Funding
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
